Sachs Associates’ 20th Annual Biotech in Europe Forum

Add to calendar

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

Take me there

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com